Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
Globe Newswire•24/09/2026•08:00 ET
0
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP)
VANCOUVER, Wash. and NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced additional details for the company’s planned global, multi-center Phase 2 STORYLINE clinical trial evaluating ABS-201, an investigational anti-prolactin receptor (PRLR) antibody engineered with Absci’s generative AI platform, for endometriosis.
Get started
Create a free account to read the full story and Whiz Insights.